{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:02:55Z","timestamp":1790197375887,"version":"4.1.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamaoncol.2020.5585","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:46:04Z","timestamp":1605807964000},"page":"132","source":"Crossref","is-referenced-by-count":39,"title":["Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models"],"prefix":"10.1001","volume":"7","author":[{"given":"Elizabeth","family":"Hill","sequence":"first","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dew","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"John P. Murtha Cancer Center, Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candis","family":"Morrison","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Yuan","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"cld200038r1","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"7","key":"cld200038r2","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"6","key":"cld200038r3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"cld200038r4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","article-title":"State of the science in smoldering myeloma: should we be treating in the clinic?","volume":"46","author":"Hill","year":"2019","journal-title":"Semin Oncol"},{"issue":"2","key":"cld200038r5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"cld200038r6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jamaoncol.2019.4659","article-title":"Moving from cancer burden to cancer genomics for smoldering myeloma: a review.","volume":"6","author":"Maura","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2773111\/jamaoncology_hill_2020_ld_200038_1609897917.82592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:24:56Z","timestamp":1611246296000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2773111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.5585","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}